Cart is empty For adults with hematologic malignancies receiving chimeric antigen receptor T-cell (CAR-T) therapy, quality of life (QoL) deteriorates and physical and psychological symptoms worsen one week after infusion and then improve by six months postinfusion, according to a study published recently in Blood Advances.
Leave A Comment